Seattle Genetics Inc

Latest Seattle Genetics Inc News and Updates

  • uploads///syringe pill capsule morphine
    Earnings Report

    Seattle Genetics Posted Strong Q2 2018 Results, Stock Rose

    Seattle Genetics reported sales of $170.2 million in the second quarter, which represented 57.2% growth YoY (year-over-year).

    By Sarah Collins
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial

    On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

    By Peter Neil
  • uploads///close up drugs medical medicine
    Company & Industry Overviews

    Wall Street Is Bullish on Nektar Stock despite Stock Price Slump

    Nektar is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain.

    By Sarah Collins
  • uploads///SGEN
    Company & Industry Overviews

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

    By Kenneth Smith
  • uploads///SGEN
    Company & Industry Overviews

    What Seattle Genetics’ Bottom-Line Trend Indicates

    In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How’s Seattle Genetics Positioned?

    Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

    By Kenneth Smith
  • uploads///IONS
    Company & Industry Overviews

    A Financial Overview of Ionis Pharmaceuticals in October

    Ionis Pharmaceuticals generated Q2 2018 revenues of $118.0 million compared to $122.3 million in Q2 2017, which reflected ~15.0% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates

    Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

    By Mike Benson
  • uploads///blood _
    Company & Industry Overviews

    Why Advaxis Stock Is Soaring Today

    Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.

    By Daniel Collins
  • uploads///cells _
    Company & Industry Overviews

    CRISPR Stock Has Seen Soild Growth in the Last 12 Months

    CRISPR Therapeutics has risen 24% between May 11 and May 17.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Key Updates on Akcea Therapeutics’ Volanesorsen

    Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).

    By Mike Benson
  • uploads///Kymriah Juliet
    Company & Industry Overviews

    Key Updates on Novartis’s Kymriah

    In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

    By Daniel Collins
  • uploads///Opdivo
    Company & Industry Overviews

    Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb

    In 1Q17, 2Q17, and 3Q17, Opdivo reported revenues of $1.1 billion, $1.2 billion, and $1.3 billion, respectively.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in November 2017

    In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.

    By Daniel Collins
  • uploads///Analysts reco
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in August 2017

    In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in June 2017

    Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”

    By Daniel Collins
  • uploads///Chart  Adcetris and Opdivo
    Company & Industry Overviews

    Updates on the Adcetris and Opdivo Combination

    Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.

    By Mike Benson
  • uploads///Chart  Checkmate
    Company & Industry Overviews

    Data from the Checkmate-205 Study Evaluating Opdivo

    Follow-up data were released from the Checkmate-205 study. It evaluated long-term effects of PD-1 inhibitors in patients with classical Hodgkin Lymphoma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Is Mylan’s Generics Segment Doing?

    Mylan’s (MYL) 3Q16 revenues were mainly driven by a 17.0% rise in sales for its Generics segment. The segment reported $2.6 billion in sales in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals Doing with IONIS-TTR?

    In March 2010, Ionis entered into a preferred partner alliance with GlaxoSmithKline (GSK) for the development and commercialization of IONIS-TTR.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Existing Chemotherapy Drugs for Lymphoma

    Opdivo is under phase II study for the use in the treatment of relapsed or refractory classical Hodgkin’s lymphoma.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    XBI on a Downward Slope, but How Steep?

    On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.

    By Peter Neil
  • uploads///Pomalyst and Abraxane Revenue Part
    Earnings Report

    Pomalyst and Abraxane Revenues Are Critical for Celgene

    Pomalyst and Abraxane are the next largest revenue generators for Celgene (CELG) after Revlimid. Their revenue growth is critical for Celgene to achieve revenues of $20 billion by 2020.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Medivation and Bluebird Led IBB’s Mid-Cap Stocks Last Week

    Medivation and Bluebird led IBB’s mid-cap stocks for the week ended September 18, 2015.

    By Peter Neil
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.